# PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
Canonical URL: https://biopharmsignal.com/news/PEPG/pepgen-announces-topline-results-from-lowest-dose-5-mg-kg-mad-cohort-in-the-ongoing-phase-2-freedom2-study-demonstrating-favorable-safety-splicing-and-vhot-data
Ticker: PEPG
Company: PepGen
Source: PepGen
Published: 2026-03-30 20:05 EST
Original Source URL: https://investors.pepgen.com
## Summary

– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing

## Article Body
– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing
## Recent Company News
- 2026-05-21 11:00 EST — [PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program](https://biopharmsignal.com/news/PEPG/pepgen-announces-presentations-at-the-15th-international-myotonic-dystrophy-consortium-highlighting-clinical-data-from-the-pgn-edodm1-program) — Source: PepGen
- 2026-05-12 20:05 EST — [PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/PEPG/pepgen-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: PepGen
- 2026-03-30 20:05 EST — [PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data](https://biopharmsignal.com/news/PEPG/pepgen-announces-topline-results-from-lowest-dose-5-mg-kg-mad-cohort-in-the-ongoing-phase-2-freedom2-study-demonstrating-favorable-safety-splicing-and-vhot-data) — Source: PepGen
- 2026-03-04 21:05 EST — [PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/PEPG/pepgen-reports-fourth-quarter-and-year-end-2025-financial-results-and-recent-corporate-highlights) — Source: PepGen
- 2026-03-04 21:03 EST — [PepGen Announces Regulatory Updates on FREEDOM2](https://biopharmsignal.com/news/PEPG/pepgen-announces-regulatory-updates-on-freedom2) — Source: PepGen
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)